Ontology highlight
ABSTRACT: Introduction
Current epidemiologic literature of rheumatologic immune-related adverse events (rh-irAEs) consists of clinical trials, case reports, or smaller, single-center series. We evaluate the occurrence of rh-irAEs during immune checkpoint inhibitor (ICI) therapy from US commercial claims data.Methods
Patients newly initiating ICI therapy in commercial claims data were eligible for inclusion. Rh-irAEs were defined using ≥ 1 International Classification of Diseases (ICD)-9 or ICD-10-Clinical Modification (CM) claims for selected events, ranging from joint pain and myalgia to ankylosing spondylitis and psoriasis. The percentage of patients experiencing rh-irAEs after ICI initiation was determined.Results
A total of 5722 patients initiating an ICI between January
SUBMITTER: Anjohrin S
PROVIDER: S-EPMC8572292 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature